Ligand Pharmaceuticals (LGND) Total Current Liabilities (2010 - 2026)

Ligand Pharmaceuticals has reported Total Current Liabilities for 17 years, with the latest figure at $40.7 million in Q1 2026.

• Quarterly Total Current Liabilities fell 30.7% year-over-year to $40.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.7 million (down 30.7% YoY) and the FY2025 annual result came in at $37.4 million, up 0.9% from the prior year.
• Total Current Liabilities improved to $40.7 million in Q1 2026 per LGND's latest filing, from $37.4 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $167.9 million in Q2 2022 and troughed at $15.7 million in Q3 2023.
• A 5-year average of $55.0 million and a median of $37.4 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities surged 272.6% in 2022, then sank 88.37% in 2023.
• Over 5 years, Total Current Liabilities stood at $98.8 million in 2022, then slumped by 83.02% to $16.8 million in 2023, then surged by 121.14% to $37.1 million in 2024, then rose by 0.9% to $37.4 million in 2025, then advanced by 8.6% to $40.7 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $40.7 million, $37.4 million, and $30.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.